United States Biotechnology & Medical Research

Cullinan Therapeutics Inc (CGEM)

Track

Over the past 90 days, Cullinan Therapeutics Inc. has seen insider activity exclusively on the sell side, totaling approximately $665,876. These transactions were primarily driven by planned sales from the Chief Scientific Officer. The stock has experienced a 39.5% price increase over the same period, currently trading near its 52-week high following a positive earnings report.
Ticker: CGEM Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Cullinan Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Michaelson Jennifer
Chief Scientific Officer
2 sales — total 200,000 USD
Planned sale 6 Jul 2026
Value US$3,757,277.50 | Price 205.72 | Shares 11,895
Planned sale 6 Jul 2026
Value US$3,622,935.95 | Price 483.90 | Shares 7,723
Proposed sale 6 Jul 2026
Value US$223,335.90 | Price 14.41 | Shares 64,788
Planned sale 5 May 2026
Value US$3,116.00 | Price 15.58 | Shares 200
Planned sale 5 May 2026
Value US$113,880.00 | Price 14.60 | Shares 7,800
Proposed sale 5 May 2026
Value US$122,720.00 | Price 15.34 | Shares 8,000
Planned sale 5 Mar 2026
Value US$125,440.00 | Price 15.68 | Shares 8,000
Proposed sale 5 Mar 2026
Value US$130,400.00 | Price 16.30 | Shares 8,000
Planned sale 25 Feb 2026
Value US$25,169.20 | Price 14.14 | Shares 1,780
Proposed sale 25 Feb 2026
Value US$25,400.60 | Price 14.27 | Shares 1,780
Sale 24 Feb 2026
Value US$66,301.54 | Price 14.47 | Shares 4,582
Sale 24 Feb 2026
Value US$52,106.47 | Price 14.47 | Shares 3,601
Sale 24 Feb 2026
Value US$195,562.05 | Price 14.47 | Shares 13,515
Sale 24 Feb 2026
Value US$52,106.47 | Price 14.47 | Shares 3,601
Planned sale 23 Feb 2026
Value US$24,510.48 | Price 13.99 | Shares 1,752
Proposed sale 23 Feb 2026
Value US$23,914.80 | Price 13.65 | Shares 1,752
Sale 20 Feb 2026
Value US$59,900.76 | Price 13.62 | Shares 4,398
Sale 20 Feb 2026
Value US$223,109.22 | Price 13.62 | Shares 16,381
Planned sale 20 Feb 2026
Value US$114,400.00 | Price 14.30 | Shares 8,000
Sale 20 Feb 2026
Value US$50,966.04 | Price 13.62 | Shares 3,742
Sale 20 Feb 2026
Value US$50,966.04 | Price 13.62 | Shares 3,742
Sale 20 Feb 2026
Value US$67,854.84 | Price 13.62 | Shares 4,982
Proposed sale 20 Feb 2026
Value US$111,040.00 | Price 13.88 | Shares 8,000
Sale 12 Feb 2026
Value US$5,004.48 | Price 12.03 | Shares 416
Planned sale 22 Jan 2026
Value US$49,200.00 | Price 12.30 | Shares 4,000
Proposed sale 22 Jan 2026
Value US$46,400.00 | Price 11.60 | Shares 4,000
Sale 23 Dec 2025
Value US$99,319.22 | Price 10.01 | Shares 9,922
Planned sale 19 Dec 2025
Value US$13,463.45 | Price 10.01 | Shares 1,345
Proposed sale 19 Dec 2025
Value US$13,423.10 | Price 9.98 | Shares 1,345
Sale 18 Dec 2025
Value US$44,791.44 | Price 9.67 | Shares 4,632
Sale 18 Dec 2025
Value US$28,023.66 | Price 9.67 | Shares 2,898
Planned sale 18 Dec 2025
Value US$33,651.60 | Price 9.67 | Shares 3,480
Planned sale 15 Dec 2025
Value US$11,840.50 | Price 11.90 | Shares 995
Proposed sale 15 Dec 2025
Value US$11,860.40 | Price 11.92 | Shares 995
Planned sale 12 Dec 2025
Value US$26,592.24 | Price 12.38 | Shares 2,148
Planned sale 24 Nov 2025
Value US$49,200.00 | Price 12.30 | Shares 4,000
Proposed sale 24 Nov 2025
Value US$37,880.00 | Price 9.47 | Shares 4,000
Buy 28 Oct 2025
Value US$1,391,685.63 | Price 8.40 | Shares 165,667
Buy 17 Oct 2025
Value US$252,565.17 | Price 7.84 | Shares 32,217
Buy 16 Oct 2025
Value US$1,328,250.00 | Price 8.86 | Shares 150,000
Buy 15 Oct 2025
Value US$409,049.05 | Price 7.94 | Shares 51,500
Buy 14 Oct 2025
Value US$114,047.78 | Price 7.59 | Shares 15,032
Buy 10 Oct 2025
Value US$2,041,384.69 | Price 7.36 | Shares 277,298
Buy 9 Oct 2025
Value US$4,191,858.72 | Price 6.70 | Shares 626,043
Buy 8 Oct 2025
Value US$3,593,698.00 | Price 6.46 | Shares 556,300
Sale 25 Feb 2025
Value US$106,872.37 | Price 8.53 | Shares 12,529
Sale 25 Feb 2025
Value US$41,754.35 | Price 8.53 | Shares 4,895
Sale 25 Feb 2025
Value US$32,038.68 | Price 8.53 | Shares 3,756
Sale 25 Feb 2025
Value US$32,038.68 | Price 8.53 | Shares 3,756
Planned sale 6 Jan 2025
Value US$50,040.00 | Price 12.51 | Shares 4,000
Proposed sale 6 Jan 2025
Value US$101,440.00 | Price 12.68 | Shares 8,000
Sale 24 Dec 2024
Value US$99,708.00 | Price 11.87 | Shares 8,400
Sale 18 Dec 2024
Value US$39,729.62 | Price 11.41 | Shares 3,482
Sale 18 Dec 2024
Value US$52,851.12 | Price 11.41 | Shares 4,632
Sale 18 Dec 2024
Value US$53,547.13 | Price 11.41 | Shares 4,693
Sale 12 Dec 2024
Value US$43,682.28 | Price 12.52 | Shares 3,489
Planned sale 5 Nov 2024
Value US$125,120.00 | Price 15.64 | Shares 8,000
Planned sale 5 Sep 2024
Value US$144,720.00 | Price 18.09 | Shares 8,000
Proposed sale 5 Sep 2024
Value US$298,880.00 | Price 18.68 | Shares 16,000
Planned sale 5 Jul 2024
Value US$130,640.00 | Price 16.33 | Shares 8,000
Proposed sale 5 Jul 2024
Value US$94,068.68 | Price 16.78 | Shares 5,606
Planned sale 7 May 2024
Value US$168,516.36 | Price 30.06 | Shares 5,606
Planned sale 6 May 2024
Value US$578,705.58 | Price 28.54 | Shares 20,277
Planned sale 6 May 2024
Value US$1,049,453.86 | Price 27.82 | Shares 37,723
Proposed sale 6 May 2024
Value US$1,871,100.00 | Price 28.35 | Shares 66,000
Planned sale 1 Feb 2024
Value US$647,200.00 | Price 16.18 | Shares 40,000
Proposed sale 1 Feb 2024
Value US$605,600.00 | Price 15.14 | Shares 40,000
Planned sale 29 Jan 2024
Value US$563,600.00 | Price 14.09 | Shares 40,000
Proposed sale 29 Jan 2024
Value US$522,800.00 | Price 13.07 | Shares 40,000
Planned sale 23 Jan 2024
Value US$265,597.36 | Price 12.46 | Shares 21,316
Planned sale 22 Jan 2024
Value US$49,582.50 | Price 12.02 | Shares 4,125
Planned sale 22 Jan 2024
Value US$177,328.62 | Price 12.18 | Shares 14,559
Proposed sale 22 Jan 2024
Value US$460,400.00 | Price 11.51 | Shares 40,000
Sale 26 Dec 2023
Value US$39,473.28 | Price 9.24 | Shares 4,272
Sale 21 Dec 2023
Value US$15,810.00 | Price 8.50 | Shares 1,860
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-07 2026-07-06 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
11,895 +34.6%
205.72
US$3,757,278 		11,895 +34.6% 205.72 US$3,757,278
2026-07-07 2026-07-06 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
7,723 -34.4%
483.90
US$3,622,936 		7,723 -34.4% 483.90 US$3,622,936
2026-07-06 2026-07-06 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
64,788
14.41
US$223,336 		64,788 14.41 US$223,336
2026-05-06 2026-05-05 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
200 -0.1%
15.58
US$3,116 		200 -0.1% 15.58 US$3,116
2026-05-06 2026-05-05 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
7,800 -4.5%
14.60
US$113,880 		7,800 -4.5% 14.60 US$113,880
2026-05-05 2026-05-05 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
8,000
15.34
US$122,720 		8,000 15.34 US$122,720
2026-03-09 2026-03-05 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -4.5%
15.68
US$125,440 		8,000 -4.5% 15.68 US$125,440
2026-03-05 2026-03-05 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
8,000
16.30
US$130,400 		8,000 16.30 US$130,400
2026-02-26 2026-02-25 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
1,780 -1.0%
14.14
US$25,169 		1,780 -1.0% 14.14 US$25,169
2026-02-25 2026-02-25 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
1,780
14.27
US$25,401 		1,780 14.27 US$25,401
2026-02-25 2026-02-24 S Sale
2.8
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,582 -2.8%
14.47
US$66,302 		4,582 -2.8% 14.47 US$66,302
2026-02-25 2026-02-24 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
3,601 -2.0%
14.47
US$52,106 		3,601 -2.0% 14.47 US$52,106
2026-02-25 2026-02-24 S Sale
2.4
AHMED NADIM

President and CEO

Executive Director
13,515 -3.3%
14.47
US$195,562 		13,515 -3.3% 14.47 US$195,562
2026-02-25 2026-02-24 S Sale
3.0
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,601 -2.7%
14.47
US$52,106 		3,601 -2.7% 14.47 US$52,106
2026-02-25 2026-02-23 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
1,752 -1.0%
13.99
US$24,510 		1,752 -1.0% 13.99 US$24,510
2026-02-23 2026-02-23 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
1,752
13.65
US$23,915 		1,752 13.65 US$23,915
2026-02-23 2026-02-20 S Sale
1.5
Fenton Mary Kay

Chief Financial Officer

Officer
4,398 -3.4%
13.62
US$59,901 		4,398 -3.4% 13.62 US$59,901
2026-02-23 2026-02-20 S Sale
2.4
AHMED NADIM

President and CEO

Executive Director
16,381 -3.9%
13.62
US$223,109 		16,381 -3.9% 13.62 US$223,109
2026-02-23 2026-02-20 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -4.2%
14.30
US$114,400 		8,000 -4.2% 14.30 US$114,400
2026-02-23 2026-02-20 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
3,742 -2.0%
13.62
US$50,966 		3,742 -2.0% 13.62 US$50,966
2026-02-23 2026-02-20 S Sale
3.0
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,742 -2.8%
13.62
US$50,966 		3,742 -2.8% 13.62 US$50,966
2026-02-23 2026-02-20 S Sale
2.8
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,982 -2.9%
13.62
US$67,855 		4,982 -2.9% 13.62 US$67,855
2026-02-20 2026-02-20 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
8,000
13.88
US$111,040 		8,000 13.88 US$111,040
2026-02-13 2026-02-12 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
416 -0.3%
12.03
US$5,004 		416 -0.3% 12.03 US$5,004
2026-01-23 2026-01-22 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
4,000 -3.0%
12.30
US$49,200 		4,000 -3.0% 12.30 US$49,200
2026-01-22 2026-01-22 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
4,000
11.60
US$46,400 		4,000 11.60 US$46,400
2025-12-29 2025-12-23 S Sale
2.4
AHMED NADIM

President and CEO

Executive Director
9,922 -2.3%
10.01
US$99,319 		9,922 -2.3% 10.01 US$99,319
2025-12-22 2025-12-19 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
1,345 -1.0%
10.01
US$13,463 		1,345 -1.0% 10.01 US$13,463
2025-12-19 2025-12-19 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
1,345
9.98
US$13,423 		1,345 9.98 US$13,423
2025-12-19 2025-12-18 S Sale
2.8
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,632 -2.7%
9.67
US$44,791 		4,632 -2.7% 9.67 US$44,791
2025-12-19 2025-12-18 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
2,898 -2.1%
9.67
US$28,024 		2,898 -2.1% 9.67 US$28,024
2025-12-19 2025-12-18 PlS Planned sale
3.0
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,480 -2.5%
9.67
US$33,652 		3,480 -2.5% 9.67 US$33,652
2025-12-16 2025-12-15 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
995 -0.7%
11.90
US$11,840 		995 -0.7% 11.90 US$11,840
2025-12-15 2025-12-15 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
995
11.92
US$11,860 		995 11.92 US$11,860
2025-12-16 2025-12-12 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
2,148 -1.5%
12.38
US$26,592 		2,148 -1.5% 12.38 US$26,592
2025-11-25 2025-11-24 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
4,000 -2.8%
12.30
US$49,200 		4,000 -2.8% 12.30 US$49,200
2025-11-24 2025-11-24 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
4,000
9.47
US$37,880 		4,000 9.47 US$37,880
2025-10-30 2025-10-28 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
165,667 +1.9%
8.40
US$1,391,686 		165,667 +1.9% 8.40 US$1,391,686
2025-10-21 2025-10-17 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
32,217 +0.4%
7.84
US$252,565 		32,217 +0.4% 7.84 US$252,565
2025-10-21 2025-10-16 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
150,000 +1.7%
8.86
US$1,328,250 		150,000 +1.7% 8.86 US$1,328,250
2025-10-21 2025-10-15 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
51,500 +0.6%
7.94
US$409,049 		51,500 +0.6% 7.94 US$409,049
2025-10-21 2025-10-14 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
15,032 +0.2%
7.59
US$114,048 		15,032 +0.2% 7.59 US$114,048
2025-10-10 2025-10-10 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
277,298 +3.4%
7.36
US$2,041,385 		277,298 +3.4% 7.36 US$2,041,385
2025-10-10 2025-10-09 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
626,043 +8.2%
6.70
US$4,191,859 		626,043 +8.2% 6.70 US$4,191,859
2025-10-10 2025-10-08 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
556,300 +7.8%
6.46
US$3,593,698 		556,300 +7.8% 6.46 US$3,593,698
2025-02-27 2025-02-25 S Sale
2.4
AHMED NADIM

President and CEO

Executive Director
12,529 -2.8%
8.53
US$106,872 		12,529 -2.8% 8.53 US$106,872
2025-02-27 2025-02-25 S Sale
2.8
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,895 -2.7%
8.53
US$41,754 		4,895 -2.7% 8.53 US$41,754
2025-02-27 2025-02-25 S Sale
3.0
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,756 -2.7%
8.53
US$32,039 		3,756 -2.7% 8.53 US$32,039
2025-02-27 2025-02-25 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
3,756 -2.6%
8.53
US$32,039 		3,756 -2.6% 8.53 US$32,039
2025-01-07 2025-01-06 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
4,000 -4.0%
12.51
US$50,040 		4,000 -4.0% 12.51 US$50,040
2025-01-06 2025-01-06 PrS Proposed sale
3.1
JENNIFER MICHAELSON

Officer

Officer
8,000
12.68
US$101,440 		8,000 12.68 US$101,440
2024-12-27 2024-12-24 S Sale
2.4
AHMED NADIM

President and CEO

Executive Director
8,400 -3.1%
11.87
US$99,708 		8,400 -3.1% 11.87 US$99,708
2024-12-20 2024-12-18 S Sale
3.0
SUMER JACQUELYN L

Chief Legal Officer

Officer
3,482 -3.7%
11.41
US$39,730 		3,482 -3.7% 11.41 US$39,730
2024-12-20 2024-12-18 S Sale
2.8
Jones Jeffrey Alan

Chief Medical Officer

Officer
4,632 -3.9%
11.41
US$52,851 		4,632 -3.9% 11.41 US$52,851
2024-12-20 2024-12-18 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
4,693 -4.5%
11.41
US$53,547 		4,693 -4.5% 11.41 US$53,547
2024-12-16 2024-12-12 S Sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
3,489 -3.2%
12.52
US$43,682 		3,489 -3.2% 12.52 US$43,682
2024-11-07 2024-11-05 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -6.9%
15.64
US$125,120 		8,000 -6.9% 15.64 US$125,120
2024-09-09 2024-09-05 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -6.5%
18.09
US$144,720 		8,000 -6.5% 18.09 US$144,720
2024-09-05 2024-09-05 PrS Proposed sale
3.1
JENNIFER MICHAELSON & MARC D MICHAELSON

Officer

Officer
16,000
18.68
US$298,880 		16,000 18.68 US$298,880
2024-07-09 2024-07-05 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
8,000 -6.1%
16.33
US$130,640 		8,000 -6.1% 16.33 US$130,640
2024-07-05 2024-07-05 PrS Proposed sale
3.1
JENNIFER MICHAELSON & MARC D MICHAELSON

Officer

Officer
5,606
16.78
US$94,069 		5,606 16.78 US$94,069
2024-05-08 2024-05-07 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
5,606 -4.1%
30.06
US$168,516 		5,606 -4.1% 30.06 US$168,516
2024-05-08 2024-05-06 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
20,277 -13.5%
28.54
US$578,706 		20,277 -13.5% 28.54 US$578,706
2024-05-08 2024-05-06 PlS Planned sale
3.1
Michaelson Jennifer

Chief Scientific Officer

Officer
37,723 -20.1%
27.82
US$1,049,454 		37,723 -20.1% 27.82 US$1,049,454
2024-05-06 2024-05-06 PrS Proposed sale
3.1
JENNIFER MICHAELSON & MARC D MICHAELSON

Officer

Officer
66,000
28.35
US$1,871,100 		66,000 28.35 US$1,871,100
2024-02-02 2024-02-01 PlS Planned sale
Savill Corrine

Chief Business Officer

Officer
40,000 -19.4%
16.18
US$647,200 		40,000 -19.4% 16.18 US$647,200
2024-02-01 2024-02-01 PrS Proposed sale
CORINNE SAVILL

Officer

Officer
40,000
15.14
US$605,600 		40,000 15.14 US$605,600
2024-01-30 2024-01-29 PlS Planned sale
Savill Corrine

Chief Business Officer

Officer
40,000 -19.4%
14.09
US$563,600 		40,000 -19.4% 14.09 US$563,600
2024-01-29 2024-01-29 PrS Proposed sale
CORINNE SAVILL

Officer

Officer
40,000
13.07
US$522,800 		40,000 13.07 US$522,800
2024-01-24 2024-01-23 PlS Planned sale
Savill Corrine

Chief Business Officer

Officer
21,316 -11.4%
12.46
US$265,597 		21,316 -11.4% 12.46 US$265,597
2024-01-24 2024-01-22 PlS Planned sale
Savill Corrine

Chief Business Officer

Officer
4,125 -2.4%
12.02
US$49,582 		4,125 -2.4% 12.02 US$49,582
2024-01-24 2024-01-22 PlS Planned sale
Savill Corrine

Chief Business Officer

Officer
14,559 -7.9%
12.18
US$177,329 		14,559 -7.9% 12.18 US$177,329
2024-01-22 2024-01-22 PrS Proposed sale
CORINNE SAVILL

Officer

Officer
40,000
11.51
US$460,400 		40,000 11.51 US$460,400
2023-12-27 2023-12-26 S Sale
2.4
AHMED NADIM

President and CEO

Executive Director
4,272 -3.7%
9.24
US$39,473 		4,272 -3.7% 9.24 US$39,473
2023-12-22 2023-12-21 S Sale
2.8
Jones Jeffrey Alan

Chief Medical Officer

Officer
1,860 -3.2%
8.50
US$15,810 		1,860 -3.2% 8.50 US$15,810
Explore more

More insider trading research around Cullinan Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America